{"cells":[{"cell_type":"code","execution_count":8,"metadata":{"execution":{"iopub.execute_input":"2023-04-14T22:59:45.622634Z","iopub.status.busy":"2023-04-14T22:59:45.622217Z","iopub.status.idle":"2023-04-14T23:00:02.416542Z","shell.execute_reply":"2023-04-14T23:00:02.414984Z","shell.execute_reply.started":"2023-04-14T22:59:45.622599Z"},"trusted":true},"outputs":[{"name":"stdout","output_type":"stream","text":["\u001b[38;5;2m✔ Created dataset 'ner_combine_filtered' in database SQLite\u001b[0m\n","\u001b[38;5;2m✔ Imported 777 annotations to 'ner_combine_filtered' (session\n","2023-04-23_15-07-30) in database SQLite\u001b[0m\n","Found and keeping existing \"answer\" in 777 examples\n"]}],"source":["!prodigy db-in ner_combine_filtered ner_C07K_combine_filtered.jsonl"]},{"cell_type":"code","execution_count":10,"metadata":{},"outputs":[{"name":"stdout","output_type":"stream","text":["\u001b[38;5;4mℹ Using CPU\u001b[0m\n","\u001b[38;5;4mℹ To switch to GPU 0, use the option: --gpu-id 0\u001b[0m\n","\u001b[1m\n","========================= Generating Prodigy config =========================\u001b[0m\n","\u001b[38;5;4mℹ Auto-generating config with spaCy\u001b[0m\n","\u001b[38;5;4mℹ Using config from base model\u001b[0m\n","\u001b[38;5;2m✔ Generated training config\u001b[0m\n","\u001b[1m\n","=========================== Initializing pipeline ===========================\u001b[0m\n","[2023-04-23 15:08:13,274] [INFO] Set up nlp object from config\n","Components: ner\n","Merging training and evaluation data for 1 components\n","  - [ner] Training: 232 | Evaluation: 57 (20% split)\n","Training: 192 | Evaluation: 44\n","Labels: ner (3)\n","[2023-04-23 15:08:13,423] [INFO] Pipeline: ['tok2vec', 'tagger', 'parser', 'attribute_ruler', 'lemmatizer', 'ner']\n","[2023-04-23 15:08:13,423] [INFO] Resuming training for: ['ner', 'tok2vec']\n","[2023-04-23 15:08:13,428] [INFO] Created vocabulary\n","[2023-04-23 15:08:13,429] [INFO] Finished initializing nlp object\n","[2023-04-23 15:08:13,429] [INFO] Initialized pipeline components: []\n","\u001b[38;5;2m✔ Initialized pipeline\u001b[0m\n","\u001b[1m\n","============================= Training pipeline =============================\u001b[0m\n","Components: ner\n","Merging training and evaluation data for 1 components\n","  - [ner] Training: 232 | Evaluation: 57 (20% split)\n","Training: 192 | Evaluation: 44\n","Labels: ner (3)\n","\u001b[38;5;4mℹ Pipeline: ['tok2vec', 'tagger', 'parser', 'attribute_ruler',\n","'lemmatizer', 'ner']\u001b[0m\n","\u001b[38;5;4mℹ Frozen components: ['tagger', 'parser', 'attribute_ruler',\n","'lemmatizer']\u001b[0m\n","\u001b[38;5;4mℹ Initial learn rate: 0.001\u001b[0m\n","E    #       LOSS TOK2VEC  LOSS NER  ENTS_F  ENTS_P  ENTS_R  SPEED   SCORE \n","---  ------  ------------  --------  ------  ------  ------  ------  ------\n","  0       0          0.00     41.88    0.00    0.00    0.00  3969.25    0.00\n","  7    1000          0.00   8190.20   62.63   58.28   67.69  4131.13    0.63\n"," 19    2000          0.00   4013.96   62.27   59.44   65.38  3862.46    0.62\n","\u001b[38;5;2m✔ Saved pipeline to output directory\u001b[0m\n","NER_model_filtered/model-last\n"]}],"source":["!prodigy train NER_model_filtered --ner ner_combine_filtered --training.max_steps=2000 --training.optimizer.learn_rate=0.001 --base-model=en_core_web_sm"]},{"cell_type":"code","execution_count":11,"metadata":{},"outputs":[{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A method of preparing an \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    antibody suitable\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," for use in a canine is provided. Also provided are caninised antibodies which specifically bind to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine neuronal growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",") and neutralise the ability of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," to bind to the p75 or \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    TrkA canine NGF receptor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". The invention extends to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    nucleic acids\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n","</mark>\n"," encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    nucleic acids\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n","</mark>\n",".</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"name":"stderr","output_type":"stream","text":["/Users/ktgiahieu/miniconda3/lib/python3.10/site-packages/spacy/displacy/__init__.py:211: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n","  warnings.warn(Warnings.W006)\n"]},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">_____d:</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Field of the Invention</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The present invention relates to antibodies, and fragments thereof, which act as antagonists of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine nerve growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". The invention extends to methods of preparing same and to the therapeutic use of these antibodies and fragments in treating conditions associated with \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    nerve growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," such as \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", pain related disorders and conditions which result in the occurrence of chronic pain in canines.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background to the Invention</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Nerve growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",") is a naturally occurring \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    secreted protein\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," which consists of an \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    alpha\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", beta and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    gamma polypeptide chain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". NGF is a member of the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    neurotrophin family\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," and is implicated in a number of different roles. NGF \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    promotes survival\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," and differentiation of sensory and sympathetic neurons and signals via two membrane bound receptors, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    p75\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    low affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," receptor and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    TrkA\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", a transmembrane tyrosine kinase and a high affinity NGF receptor. The binding of NGF to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    TrkA\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," or p75 results in an upregulation of neuropeptides in \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    sensory neurons\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",".</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The use of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," antagonists to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    treat pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," and pain sensitivity in humans has been described (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Cattaneo A.\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", Curr. Op. Mol. Ther. 2010 12(1):94-106). For example, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    International Patent Application\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," No. WO 2006/131951 describes a humanised form of the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    rat alphaD11\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    α11\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", aD11) \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    monoclonal antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". The \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    αD11 antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," has \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding specificity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," to mouse \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", but is also known to bind to human and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    rat forms\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," of NGF. Humanisation of the αD11 rat derived monoclonal antibody is required prior to administration to humans in order to minimise the production of neutralising antibodies which result from a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    human anti-mouse antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    HAMA\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",") response being mounted against rodent derived antibodies. Furthermore, the replacement of mouse \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    constant domains\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," with \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    human constant domains\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," allows \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    downstream effector\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," functions to be selected for.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Pain management in canines is currently provided through administration of analgesic drugs of several classes, including local and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    general anaesthetics\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", opioid analgesics, α2 agonists, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    non-steroidal\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," anti-inflammatory drugs (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NSAIDs\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",") and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    steroids\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". Each of these needs to be administered frequently and also has limitations in efficacy and safety. There is accordingly a need for an infrequently dosed, long lasting and efficacious form of pain relief for \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canines\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," suffering from \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    chronic pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",", such as those with \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    cancer pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," or arthritis.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">While NGF is expressed in canine tissues and the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF molecule\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," has been characterised (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Eisele I. Wood\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," IS. \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    German AJ\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Hunter L. Trayhurn P.&quot; Adipokine gene expression\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," in dog adipose tissues and dog white adipocytes differentiated in primary culture&quot; \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Hormone &amp; Metabolic Research\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". 37(8):474-81, 2005 Genbank XP_540250), no antagonist to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," has been described, nor has the use of blocking \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," mediated signalling in canines to prevent or alleviate pain. The use in canines of known antibodies which act as \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    anti-NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," antagonists in other species would not be feasible due to the production of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    neutralising antibodies\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". Furthermore, the production of a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    chimeric antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," comprising \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine derived constant domains\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    variable domains\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," derived from a known \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    anti-NGF antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," such as \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    alphaD11\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," could not be guaranteed to bind to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". Furthermore, such an antibody may exhibit \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    cross-reactivity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," to other target epitopes which may be present in canines, but not present in the species from which the antibody was originally derived. Furthermore, the production of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    neutralising antibodies\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," would limit the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    long term therapeutic administration\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," of the antibody, this being a particularly important requirement when treating a chronic pain related condition or a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    cancerous condition\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n",". Likewise, the production of a caninised form of an \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    anti-NGF antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," using \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    CDR\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," grafting, or a related technique may also result in \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    neutralising antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," production and may further exhibit a reduction in \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    antigen binding affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," and avidity. Accordingly, there is a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    serious need\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," for \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding members\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," which act as antagonists of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," for use in pain management in canines, wherein the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding members retain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," high levels of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Term</span>\n","</mark>\n"," and avidity, while avoiding the production of neutralising antibodies there against.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Summary of the invention</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"}],"source":["import spacy\n","c07k=open('../../C07K.txt').read().strip()\n","patent_lines = c07k.split('\\n')\n","\n","nlp_ner = spacy.load(\"./NER_model_filtered/model-best\")\n","\n","colors = {\"TECH\": \"#7DF6D9\", \"MEDICALCONDITION\":\"#FFFFFF\"}\n","options = {\"colors\": colors} \n","\n","for line in patent_lines[10000:10010]:\n","    doc = nlp_ner(line)\n","    spacy.displacy.render(doc, style=\"ent\", options= options, jupyter=True)"]},{"cell_type":"code","execution_count":null,"metadata":{},"outputs":[],"source":[]}],"metadata":{"kernelspec":{"display_name":"Python 3","language":"python","name":"python3"},"language_info":{"codemirror_mode":{"name":"ipython","version":3},"file_extension":".py","mimetype":"text/x-python","name":"python","nbconvert_exporter":"python","pygments_lexer":"ipython3","version":"3.10.8"}},"nbformat":4,"nbformat_minor":4}
